Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Otsuka to Pay $865 Million For Europe and China Rights to Akebia's Anemia Treatment

publication date: May 12, 2017
Japan's Otsuka Pharma signed a $865 million deal to add non-US rights (including China) for a late-stage anemia drug from Boston's Akebia Therapeutics. Late in 2016, Otsuka entered a $1 billion agreement for US rights to vadadustat, an oral hypoxia-inducible factor stabilizer. The latest deal adds rights in Europe, China, Russia, Canada, Australia and the Middle East. Akebia will receive $73 million upfront and up to $792 million in development funding and milestone payments for the non-US rights. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here